Perspectives of Japanese oncologists on the health economics of innovative XXXX treatments.

@entity1 @entity5
BACKGROUND: Few reports have thus far discussed the influence of economic factors on treatment decision-making by @entity1 . The objective of the present study was to clarify the awareness among oncologists of health economics in @entity5 treatment. METHODS: The present study was based on the questionnaire regarding health economics in @entity5 treatment carried out by the Japan Society of Clinical Oncology  (JSCO) in July 2013. The subjects were trustees registered with JSCO. The survey investigated the influence of medical expenses on @entity1 access to and selection of medical treatment in order to clarify the primary attributes of the respondents and their awareness of economics. The study also investigated the maximum allowable public medical expenses to prolong the life expectancy of a @entity5 @entity1 by 1  year and the factors that can influence treatment selection. RESULTS: The 172 respondents had completed a mean of 30.3      6.2 postgraduate years, and the mean number of @entity1 they treated annually was 1323      1963. The degree of treatment accessibility among @entity1 was perceived positively by 112 (71.3  %) and negatively by 49 (28.7  %) of the respondents, irrespective of medical expenses. Of the 172 respondents, 66 (41.0  %) believed that the maximum allowable medical expenses for @entity5 treatment should be  <=4 million yen/LY, with 62 (39.8  %) reporting a value of 4.01-8 million yen/LY. CONCLUSION: The findings of this study suggest that a certain range of medical expenses has come to be regarded as the standard range of medical expenses for @entity5 treatment among oncologists, with answers based on the premise that @entity1 should have access to effective medical treatment.
